financial statements 151 Hikma PHarmaceuticals Plc annual report 2011 53. long-term incentive plans ltips the details of the ltiP scheme are provided in note 36 to the Group accounts.
as at 31 December 2011, the total number of awards granted toemployees of the company under the ltiPs during the life of the plans was 1,123,000 shares 2010: 896,000 and the total amount of the compensation expenses charged to the statement of comprehensive income is usD 1,818,000 2010: usD 874,000.
54. share capital 2011 2010 issued and fully paid included in shareholders equity: $000 $000 195,851,307 2010: 193,516,989 ordinary shares of 10 pence each 34,904 34,525 Details of the issue of share capital in the year are given in note 31 to the Group accounts.
55. share premium share premium $000 Balance at 1 January 2011 Restated 275,968 premium arising on exercise of stock options 2,126 Balance at 31 December 2011 278,094 usD 707,369,000 pertaining to the Group reorganisation in 2005 was reclassified from share premium to merger reserve.
56. net income for the year as permitted by section 408 of the companies act 2006, the statement of comprehensive income of the company is not presented as part ofthese accounts.
the net income in the company for the year is usD 67,867,000 2010: usD 4,989,000. included in the net income for the year is an amount of usD 75,557,000 2010: usD 12,282,000 representing dividends received and usD1,818,000 2010: usD 899,000 representing the current year charge of ltiPs expenses relating to the companys employees.
the remaining usD 5,689,000 2010: usD 3,574,000 of the Groups stock option, ltiPs and miPs charge is recharged to subsidiary companies.
57. related party Darhold Limited: is a related party of the company because it is considered one of the major shareholders of Hikma Pharmaceuticals Plc withownership percentage of 29.2% at the end of 2011 2010: 29.5%.
further details on the relationship between mr. samih Darwazah, mr. said Darwazah, mr. mazen Darwazah and mr. ali al-Husry, and Darhold limited are given in the Directors report.
amounts repayable to and from subsidiaries are disclosed in notes 45 and 48.
Other transactions with related parties include management charges for services provided to the subsidiary companies, equity settled employee share scheme costs relating to the subsidiary companies and transactions with key management personnel.
compensation paid tokeymanagement personnel is disclosed in note 38.
Details of Directors remuneration are disclosed in the remuneration committee report onpages 76 to 90. more details on the general information of the ultimate parent of the Group are disclosed in note 2.
